Abstract
Recently particulate systems like nanoparticles have been used as a physical approach to alter and improve the pharmacokinetic and pharmacodynamic properties of various types of drug molecules. They have been used in vivo to protect the drug entity in the systemic circulation, restrict access of the drug to the chosen sites and to deliver the drug at a controlled and sustained rate to the site of action.Drug delivery research is clearly moving from the micro- to the nanosize scale. Nanotechnology is therefore emerging as a field in medicine that is expected to elicit significant therapeutic benefits. The development of effective nanodelivery systems capable of carrying a drug specifically and safely to a desired site of action is one of the most challenging tasks of pharmaceutical formulation investigators. They are attempting to reformulate and add new indications to the existing blockbuster drugs to maintain positive scientific outcomes and therapeutic breakthroughs. The nanodelivery systems mainly include nanoemulsions, lipid or polymeric Nanoparticles and liposomes.For the past few years, there has been a considerable research on the basis of Novel drug delivery system, using particulate vesicle systems as such drug carriers for small and large molecules. Nanoparticles have been improving the therapeutic effect of drugs and minimize the side effects. Basically, Nanoparticles have been prepared by using various techniques as such dispersion of preformed polymers, polymerization of monomers and ionic gelation or co-acervation of hydrophilic polymer.
References
Gaur A. and Bhatia A. L, Asian J. Exp. Sci. 2008,22 :51- 62.
Mishra B., Bhavesh B., Patel B. B., TIwari 5., Nanomedicine: Nanotechnology, Biology, and Medicine 2010, 6: 9 -24.
Alexis E, Rhee J.W., Richie J.P., Radovic-Moreno A.E, Robert langer R., FarokhzadO.C, UrolOncol 2008,26:74-85.
la-Van D., McGuire 1:, langer R., Nat Biotechnol 2003,21:1184-91.
Reverchon E and Adami R. Nanomaterial and supercritical fluids. 2006;37:1-22.
Rolland JP, Maynor BW, Eullis LE, Exner AE, Denison GM and Desimonal JM. Direct fabrication and harvesting of monodispersed shape specific nanobiomaterial. J Am Chem Soc. 2005;127:10096-10100.
KompellaUB, Bandi N, Ayalasomayajula SP. Poly(lactic acid) nanoparticles for sustained release of bubesonide. Drug deliv Technol. 2001;1:1-7.
Li YP, Pei YY, Zhou ZH, Zhang XY, GuZH and Ding J. Nanoparticles as tumornecrosis factor-[alpha] carriers. J control release. 2001;71:287-296.
Zhang Q, Shen Z and Nagai T. Prolonged hypoglycemic effect of insulin-loaded polybutylcyanoacrylatenanoparticles after pulmonary administration to normal rats. Int J Pharm. 2001;218:75- 80.
Boudad H, Legrand P, Lebas G, CheronM, Duchene D and Ponchel G. Combined Hydroxypropyl-[beta]- cyclodextrins ;nanoparticles intended for oral administration of sequinarvir. Ind J Pharm. 2001;218:113-124.
Puglisi G, Fresta M, Gimmona G and Ventura CA. Influence of the prepration condition on poly(ethylcyanoacrylate) IJRPC 2012, 2(3) PrabhjotKaur et al ISSN: 2231-2781761nanocapsules formation. Ind J Pharm. 1995;125:283-287. 12. Calvo P, Remunan- Lopez C, Vila-JatoJL and Alonso MJ. Novel hydrophilic chitosan –polyethylene oxide nanoparticles as protein carrier.J Appl Polymer Sci. 1997;63:125-132.
Kroil RA, Pagel MA, Muldoon LL, Roman-Golstein S, Flamengo SA and Neuwet EA. Improving drug delivery tiintracerabletumor and surrounding brain in a rodent model;comparsion of osmatic and bradyknin modification of blood tumor barrier. Neurological.
1998;43:879-886.
Kreuter J, Ramage PV, Hamm S, Gelpenia SE, Engeltatdt B and AlyantdinRyvonBriesen H. Direct evidence that polysorbate -80 coated poly (butylcyanocrylate) nanoparticles deliver drugs to the CNS via specific mechanisms required prior binding of drug to the nanoparticles. PhrmRes.2003;20:409-16.
Puglisi G, FrestaM ,Giammona G and Ventura CA. Influence of the preparation conditions on poly(etyhycyanoacrylate) nanocapsules formation. Ind J Pharm.1995;125:283-287.
Couvreur P, Barratt G, Fattal E, Legrand P, Vanthier C. Nanocapsule technology; a review. Crit Res Ther drug carrier syst. 2002;19:99-134.
Champeau Rachel. Assessing safety health risks of nanomaterials. 2006;15:2005.
Jin Y, Wu M and Zhaox. Toxicity of nanomaterials to living cells.2005:274-277.
Delvecchio Rick. Berkeley considering need for nano safety.articles.sfgate.com;2006.
Langer R. Biomaterials in drug delivery and tissue engineering; one labortory’s experience. Acc ChemRes.2000;33:94-101.
Bhadia D, Bhadra S, Jain P and Jain NK. Pegnology; a review of PEGylated systems; Pharmazin. 2002;57:5- 20.
Kommaleddy S, Tiwari SB and Amiji MM. Long circulating polymeric nanovectors for tumour selective gene delivery technol. cancer Res Treat. 2005;4:615-25
Theresa Phillipos. Nanoparticles safe !About .co.Guide; 2009.
Cincinnati, OH,Approaches to safe nano-technology; an iformation exchange with NIOSH; 2006, www.(dc.gov/niosh/topics/nano/exchange.hmt.)
Cho K, Wang X, Nie S, et al. Therapeutic nanoparticles for drug delivery in cancer. Clin
Cancer Res 2008; 14:1310–1316.
Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008; 127:97–109.
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright (c) 2020 Array